SCHEMBL6713728

SCHEMBL6713728

[S]c1cccc2c1CCCC2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 1/20 0.56
BAD Q92934 1/20 0.56
TSHR P16473 2/20 0.48
ALDH1A1 P00352 5/20 0.39
HTT P42858 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
LMNA P02545 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
NOS3 P29474 1/20 0.38
NOS1 P29475 1/20 0.38
NOS2 P35228 1/20 0.38
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2A Q12879 1/20 0.38
GRIN2B Q13224 1/20 0.38
GRIN2C Q14957 1/20 0.38
GRIN3A Q8TCU5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4974372 0.75 BCL2L1 (0.60) BCL2L1BADTSHRALDH1A1HTT
SCHEMBL5530397 0.73 BCL2L1 (0.58) BCL2L1BADTSHRALDH1A1HTT
SCHEMBL598625 0.73 BCL2L1 (0.58) BCL2L1BADTSHRALDH1A1HTT
SCHEMBL30717272 0.73 BCL2L1 (0.58) BCL2L1BADTSHRALDH1A1HTT
Bromide SCHEMBL7104246 0.73 BCL2L1 (0.58) BCL2L1BADTSHRALDH1A1HTT
SCHEMBL6714002 0.71 BCL2L1 (0.56) BCL2L1BADTSHRALDH1A1HTT
SCHEMBL1513618 0.71 BCL2L1 (0.56) BCL2L1BADTSHRALDH1A1HTT
SCHEMBL751800 0.71 BCL2L1 (0.56) BCL2L1BADTSHRALDH1A1HTT
SCHEMBL4542560 0.71 BCL2L1 (0.56) BCL2L1BADTSHRALDH1A1HTT
SCHEMBL5489112 0.71 BCL2L1 (0.56) BCL2L1BADTSHRALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040127433-A1 excellent antibacterial activity especially against a typical acid-fast mycobacteria including multiple drug-resistant bacteria HOKURIKU SEIYAKU CO., LTD. (JP) 2004-07-01 US disclosed
EP-1323726-A1 ERYTHROMYCIN DERIVATIVES AND MEDICINES CONTAINING THE SAME HOKURIKU SEIYAKU CO., LTD. (JP) 2003-07-02 EP disclosed
EP-1167375-A1 ERYTHROMYCIN DERIVATIVES HOKURIKU SEIYAKU CO., LTD. (JP) 2002-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127433-A1 excellent antibacterial activity especially against a typical acid-fast mycobacteria including multiple drug-resistant bacteria MAPRE1, MAPRE2, MRPS27 BCL2L1 989/4885BAD 1900/4885TSHR 925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.